{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-009831","form_type":"8-K","ticker":"PLSE","cik":"0001625101","company_name":"PULSE BIOSCIENCES, INC.","filed_at":"2024-03-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.852042+00:00","generated_at":"2026-06-04T06:12:42.442404+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Pulse Biosciences reports FY2023 net loss of $42.2M; plans $60M rights offering","bullets":["GAAP net loss FY 2023 ($42.2M) vs ($58.5M) in 2022; Q4 net loss ($11.9M) vs ($9.2M) prior year.","Cash and equivalents $44.4M at Dec 31, 2023, down from $61.1M a year earlier.","FDA 510(k) clearance for CellFX nsPFA Percutaneous Electrode for non-cardiac soft tissue ablation.","Rights offering of up to $60M in Units (share + warrants) to existing holders; record date in April.","Chairman Robert Duggan supports and intends to participate in rights offering on same terms."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-009831","json":"https://secwatch.observer/filing/0001437749-24-009831.json","markdown":"https://secwatch.observer/filing/0001437749-24-009831.md","text":"https://secwatch.observer/filing/0001437749-24-009831.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1625101/000143774924009831/0001437749-24-009831-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1625101/000143774924009831/plse20240327_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T06:12:42.442404+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"87938e511ecca00da2a0c9057f8c119045c85cea","claim":"PULSE BIOSCIENCES, INC. reported the fiscal quarter and full year ended December 31, 2023 results: net income ($11.9) million.","evidence_excerpt":"On March 28, 2024, Pulse Biosciences, Inc. (the “Company”) announced its financial and operational results for the fiscal quarter and full year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1625101/000143774924009831/0001437749-24-009831-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal quarter and full year ended December 31, 2023"},{"label":"Net income","value":"($11.9) million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}